How to improve R&D productivity: the pharmaceutical industry's grand challenge
Top Cited Papers
- 19 February 2010
- journal article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 9 (3) , 203-214
- https://doi.org/10.1038/nrd3078
Abstract
The pharmaceutical industry is under growing pressure from a range of environmental issues, including major losses of revenue owing to patent expirations, increasingly cost-constrained healthcare systems and more demanding regulatory requirements. In our view, the key to tackling the challenges such issues pose to both the future viability of the pharmaceutical industry and advances in healthcare is to substantially increase the number and quality of innovative, cost-effective new medicines, without incurring unsustainable R&D costs. However, it is widely acknowledged that trends in industry R&D productivity have been moving in the opposite direction for a number of years. Here, we present a detailed analysis based on comprehensive, recent, industry-wide data to identify the relative contributions of each of the steps in the drug discovery and development process to overall R&D productivity. We then propose specific strategies that could have the most substantial impact in improving R&D productivity.Keywords
This publication has 31 references indexed in Scilit:
- A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primatesProceedings of the National Academy of Sciences, 2009
- PCSK9: a convertase that coordinates LDL catabolismJournal of Lipid Research, 2009
- Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disordersJournal of Clinical Investigation, 2007
- The cost of biopharmaceutical R&D: is biotech different?Managerial and Decision Economics, 2007
- Drug discovery in jeopardyJournal of Clinical Investigation, 2006
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006
- Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliancesJournal of Health Economics, 2005
- Prospects for productivityNature Reviews Drug Discovery, 2004
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003
- The Value of Improving the Productivity of the Drug Development ProcessPharmacoEconomics, 2002